Inloggen

Login
 
Wachtwoord vergeten?

Biophytis ontploft, Integragen en Theradiag next!

Volgen
 
Klik hier om dit forumtopic te volgen en automatisch op de hoogte gehouden te worden bij nieuwe berichten.
380 Posts
Pagina: 1 2 3 4 5 6 ... 19 »» | Laatste | Omlaag ↓
  1. [verwijderd] 1 juli 2017 13:39
    Het Franse aandeel Biophytis ging deze week maar liefst 30% hoger. Waarom dan? Nou, ze hebben recent geld opgehaald en Braknor Fund heeft een belang. Het gaat deze jongens natuurlijk maar om 1 ding en dat is geld verstrekken en vervolgens er meer geld uit halen. Maar het is super goed voor het sentiment. De kans is dan ook groot dat achtergebleven en recent gefinancierde bedrijven ook een koerssprong kunnen maken. Ik heb 2 kandidaten: Theradiag en Integragen. Om met de laatste te beginnen:

    aantal uitstaande aandelen: 6 536 944
    42% in vaste handen
    huidige marktwaarde: 19 miljoen
    3.7 mln opgehaald in februari tegen EUR 2.53

    Uit een recente presentatie worden de volgende doelen voor de komende 12 maanden uiteengezet:

    lees verder op ponzi.nl/biophytis-ontploft-integrage...
  2. [verwijderd] 10 juli 2017 09:46
    Grow of partnerships in clinical genomics
    – Access new clinical genomic platforms as the sole or partner operator

    Enlarge digital genomics offering
    – Continue development of clinical sequencing offers such as circulating tumor exome, low DNA quantity
    – Develop & market bio informatics software – ICE launch in 2018
    – Grow GeCo expertise and IT support

    Successfully Launch miRpredX test
    – Licensing partners in North America and Europe
    – CE marked kit launch in European countries

    Select R&D partnerships
    – Access to clinical trials relevant for miR-31 -3p biomarker in Colorectal and Lung cancer
    – Companion Dx agreement
  3. RodgerRodger 13 februari 2020 10:35
    De handel in aandelen van Biophytis is opgeschort in afwachting van een nieuw persbericht


    Parijs (Frankrijk), Cambridge (Massachusetts, VS), 13 februari 2020, 08:00 CET - Biophytis SA (Euronext Growth Paris: ALBPS - FR0012816825) heeft Euronext Parijs gevraagd om de handel in haar aandelen vanaf vandaag 13 februari op te schorten 2020 vóór de opening van de beurs.

    ****
  4. DonSjon 13 februari 2020 17:56
    Zomaar een dag op slot.. Hoe kan dat nou?

    Afgelopen dagen immens gestegen dus hoop goed bericht. Zit er bewust niet groot in. Benieuwd of Biophytis morgen wel ´open´ is en wat het persbericht gaat zijn. Overname zou leuk zijn. Slecht nieuws dan maar pennystock voor een tijdje en wachten op een nieuwe uitbraak.
  5. RodgerRodger 14 februari 2020 08:32
    Press release
    Biophytis successfully completes a € 3.3 million capital increase to strengthen its financing structure
    Paris (France), Cambridge (USA), 14 February 2020 – 8am CET, Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company with a primary focus on the development of its lead drug candidate, Sarconeos (BIO101) for the treatment of neuromuscular diseases, announced the completion of a private placement of new shares allowing it to achieve a capital increase of approximately €3.3 million. The transaction was conducted via a private placement, which was carried out on 12 February 2019 after the market closed.
    The common shares were purchased by institutional European and U.S. investors, most of them previously invested in Biophytis
    Terms of private placement
    This private placement resulted in the issuance of 12,394,071 new common shares via a capital increase, without preferential subscription rights, or 31.6% of the shares outstanding after the transaction. For illustration purposes, a shareholder holding 1% of the share capital of the Company prior to this capital increase will experience a decrease in its holding to approximately 0.684%, assuming no purchase by it of new common shares in this private placement.
    The price of the new common shares to be issued is €0.27 per share following an accelerated book building exercise. This price corresponds to a 29.5% discount to the weighted average Biophytis stock price over the last 10 trading sessions prior to private placement. Biophytis estimates the gross proceeds of the issuing to be €3,346,399.17 million.
    Following the capital increase, the shareholding structure will be as follows:
    Shareholders
    Before capital increase After capital increase Nb of shares % Nb of shares %
    Management
    Other than management Free float
    New shareholders
    TOTAL
    1,560,937 5.82%
    1,560,937 87,620 25,164,697
    12,394,071
    39,207,325
    3.98%
    0.22% 64.18% 31.61%
    100.00%
    87,620 25,164,697
    -
    0.33% 93.85% 0.00%
    26,813,254 100.00%
    Use of funds
    Biophytis will use the net proceeds of the capital increase to strengthen its financial resources, in particular for the preparation of the MYODA clinical study in Duchenne Muscular Dystrophy (DMD), for which Sarconeos (BIO101) obtained an IND from the FDA in December 2019. This capital increase, along with the other financing instruments already in place, allows the company to secure its financial position beyond the next 12 months.
    Settlement-delivery and listing of new shares
    The settlement-delivery of the securities will take place on or about February 19, 2020, subject to the usual 1

    Press release
    conditions. The new common shares should be admitted to trading on the regulated Euronext Paris market under the existing ISIN code of Biophytis common shares by no later than February 20, 2020. The new common shares, with a face value of €0.20 euro, will rank equally with the existing common shares of Biophytis.
    In accordance with Article 211-3 of the AMF General Regulation, this offer of financial securities did not require a prospectus subject to the AMF visa.
    Detailed regulatory information regarding the Company are available in the 2018 Annual report, accessible on its website: www.biophytis.com/ , including the entirety of chapter 4 regarding risks
    Stanislas Veillet, President and CEO of Biophytis, said: "We are pleased to announce that we have successfully received commitments for a capital increase of €3.3 million. This allows Biophytis to reinforce its financing structure, and in particular for the preparation of the MYODA clinical study in Duchenne Muscular Dystrophy (DMD), for which Sarconeos (BIO101) obtained an IND from the FDA in December. I want to thank our investors who have been following us for years and have not hesitated to invest again in Biophytis at a 73% premium to last week’s lowest share price”
    ****
    About BIOPHYTIS
    Biophytis SA is a clinically staged biotechnology company specializing in the development of drug candidates to slow down degenerative processes and improve functional abilities in patients with age-related diseases, particularly neuromuscular diseases.
    Sarconeos (BIO101), our leading drug candidate, is a small molecule, administered orally, currently in clinical phase 2b in sarcopenia (SARA-INT) in the United States and Europe. A pediatric formulation of Sarconeos (BIO101) is being developed for the treatment of Duchenne myopathy (DMD) for which the company received IND status by the U.S. Food and Drug Administration (FDA) in December 2019.
    The company is based in Paris, France, and Cambridge, Massachusetts. The company's common shares are listed on the Euronext Growth Paris market (Ticker: ALBPS -ISIN: FR0012816825). For more information www.biophytis.com.
    Warning
    This press release contains forward-looking statements. While the Company considers its projections to be based 2
    This private placement was made pursuant to Article L. 411-2 II of the Monetary and Financial Code under the 12th resolution of the Extraordinary General Meeting of Shareholders held on August 8, 2019.
    The decision to conduct this capital increase was made by the Company's Board of Directors, at a meeting on 12 February 2020. This capital increase was made by issuing new common shares with the removal of the preferential right of subscription of shareholders in accordance with Article L. 225-136 of the Code of Commerce (by private placement of less than 20% of the company’s share capital).
    The private placement is led by H.C. Wainwright & Co. as the exclusive placement agent in the United States and Banque Delubac and Cie – CIB as an advisor and global coordinator of the transaction.

    Press release
    on reasonable assumptions, these forward-looking statements may be called into question by a number of hazards and uncertainties, so that actual results may differ materially from those anticipated in such forward- looking statements. For a description of the risks and uncertainties likely to affect the results, BIOPHYTIS' financial position, performance or achievements and thus cause a change from the forward-looking statements, please refer to the "Risk Factors" section of the Company's Equity Admission Prospectus for listing on the Euronext Growth market in Paris filed with the AMF and available on the AMF (www.amf-france.org) and BIOPHYTIS websites ( www.biophytis.com).
    This press release, and the information contained in it, does not constitute an offer to sell or subscribe, nor the solicitation of a purchase or subscription order, of BIOPHYTIS shares in any country. The elements contained in this communication may contain forward-looking information involving risks and uncertainties. The Company's actual achievements may differ materially from those anticipated in this information due to different risk and uncertainty factors. This press release was written in French and English; If there is a difference between the texts, the French version will prevail.
    Biophytis Contact for Investor Relations
    Evelyne Nguyen, CFO evelyne.nguyen@biophytis.com Tel:+33144272332
    Media contact
    Citigate Dewe Rogerson
    Quentin DUSSART/Sylvie BERREBI/ Nathaniel DAHAN biophytis@citigatedewerogerson.com Tel:+33(0)155307091/+44(0)2076389571
    3
  6. RodgerRodger 17 februari 2020 22:50
    quote:

    DonSjon schreef op 15 februari 2020 13:29:


    Vet balen. Op 55ct. ingestapt xD. Dat was zowat de top. Naja.. Genoeg moois in de pipeline en afgelopen maanden mooie PBs uitgekomen. Word niet voor niets voor vele $ in aandelen geïnvesteerd.

    Verkooporder 1EU ingesteld. Krijg vanzelf een mailtje wanneer die geactiveerd is :):)

    Rustig op de plank laten liggen, kijk maar naar Pharming en Novacyt.
  7. Lekker ding 8 april 2020 22:35
    Press release
    Biophytis Launches COVA Clinical Study with Sarconeos (BIO101) in Covid-19
    th
    Paris, (France), Cambridge (Massachusetts, United States), April 7 , 2020, 8:00 a.m. CEST -
    Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company specialized in the development of drug candidates for treatment of aged related diseases, amongst which neuromuscular diseases, today announces that it is joining the global effort to fight the SARS-CoV-2 virus and its effects, by launching a new clinical development program: COVA, with Sarconeos (BIO101) as a potential treatment for respiratory failure associated with Covid-19.
    The COVA clinical program consists of evaluating the therapeutic efficacy and the safety of Sarconeos (BIO101) in the treatment of Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19. The Phase 2/3 clinical trials are expected to start in the coming weeks in France, following approval from the French National Agency for the Safety of Medicines (ANSM- Agence Nationale de Sécurité du Médicament), and should then extend to Belgium and the United States. The first randomized patient is expected to be recruited at the Pitié-Salpêtrière Hospital, which is linked with Sorbonne University’s medical school, a long-standing partner of Biophytis.
    Sarconeos (BIO101) is a drug candidate that has demonstrated an excellent safety profile during the SARA development program which is evaluating its ability to improve muscle function in frail elderly patients with sarcopenia (the phase 2b study, SARA-INT, is currently underway). Sarconeos (BIO101) is also being developed to improve the respiratory function of children with Duchenne muscular dystrophy (DMD), Biophytis’ MYODA DMD program is expected to start in H2 2020.
    The COVA program builds on the clinical and preclinical data generated with Sarconeos (BIO101) in these neuromuscular diseases.
    Stanislas Veillet, President and CEO of Biophytis, said: “Covid-19 has completely transformed our society on a global scale, and has had a devastating effect particularly on the frail elderly. We are very eager to answer the calls from our industry and national and international organizations to join the global effort to fight this pandemic. Sarconeos (BIO101) has been shown to restore normal respiratory function in several experimental models by activating the renin-angiotensin system, the very one which is attacked by the SARS-Cov-2 virus. In the absence of a suitable vaccine or a proven antiviral therapy we believe that Sarconeos (BIO101) could offer an important potential treatment option for patients with acute respiratory failure associated with COVID-19, potentially limiting the need for ventilators and speeding up their potential recovery. We anticipate an approval from the ANSM (and potentially other regulatory bodies) to enable us to start our COVA program, allowing us to respond as quickly as possible to this health emergency.“

    Press release
    The Coronavirus SARS-CoV-2 can cause ARDS by disrupting the renin angiotensin system (RAS), which has a key role in regulating respiratory function. It is believed that SARS-CoV-2 enters the lung cells using the Angiotensin 2 Converting Enzyme (ACE-2), a key enzyme in the RAS, inhibiting the system’s protective arm. Sarconeos (BIO101) activates the MAS receptor, a key component of the protective arm of the RAS, and has been shown to restore respiratory function in several preclinical models.
    ****
    About BIOPHYTIS
    Biophytis SA is a clinical-stage biotechnology company specialized in the development of drug candidates to slow down degenerative processes and improve functional abilities in patients with age-related diseases, especially neuromuscular diseases.
    Sarconeos (BIO101), our leading drug candidate, is a small molecule, administered orally, currently in clinical Phase 2b in sarcopenia (SARA-INT) in the United States and Europe. A pediatric formulation of BIO101 is being developed for the treatment of Duchenne Muscular Dystrophy (DMD). The company plans to start the clinical development in H2 2020.
    Sarconeos (BIO101) will also be developed as a treatment for Covid-19 (Coronavirus) for which the company has filed a clinical trial application with the French Regulatory Authority (ANSM).
    The company is based in Paris, France, and Cambridge, Massachusetts. The company's common shares are listed on the Euronext Growth Paris market (Ticker: ALBPS -ISIN: FR0012816825). For more information www.biophytis.com.
    Disclaimer
    This press release contains forward-looking statements. While the Company considers its projections to be based on reasonable assumptions, these forward-looking statements may be called into question by a number of hazards and uncertainties, so that actual results may differ materially from those anticipated in such forward-looking statements. For a description of the risks and uncertainties likely to affect the results, BIOPHYTIS' financial position, performance or achievements and thus cause a change from the forward-looking statements, please refer to the "Risk Factors" section of the Company's 2018 Annual Report available on BIOPHYTIS website ( www.biophytis.com).
    This press release, and the information contained in it, does not constitute an offer to sell or subscribe, nor the solicitation of a purchase or subscription order, of BIOPHYTIS shares in any country. The elements contained in this communication may contain forward-looking information involving risks and uncertainties. The Company's actual achievements may differ materially from those anticipated in this information due to different risk and uncertainty factors. This press release was written in French and English; If there is a difference between the texts, the French version will prevail.

    Biophytis Contact for Investor Relations
    Evelyne Nguyen, CFO
    evelyne.nguyen@biophytis.com
    Media contact
    Citigate Dewe Rogerson
    Sylvie Berrebi/ Nathaniel Dahan/ David Dible / Quentin Dussart
    biophytis@citigatedewerogerson.com
    Tel: +44 (0) 20 7638 9571 / +33 (0)6 59 42 29 35
    Press release
  8. Aquascaper 12 april 2020 18:52
    Ik ben nieuw op dit forum en heb drie weken geleden weer mijn eerste aandelen gekocht. Biophytis is er één van maar het verbaast mij een beetje dat hier nu zo weinig discussie over is. Novacyt ging vorige week als een raket en Biophytis zit een beetje in het zelfde segment maar bij Novacyt explodeerde de discussie. Naar mijn mening ging Biophytis ook als een raket en met het laatste nieuws dat Lekker Ding ook deelde heb ik wel vertrouwen dat deze de komende periode zal blijven stijgen.

    Zijn er hier mensen die een reden kunnen benoemen waarom je juist niet moet kopen?
380 Posts
Pagina: 1 2 3 4 5 6 ... 19 »» | Laatste |Omhoog ↑

Plaats een reactie

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord

Direct naar Forum

Indices

AEX 557,08 -0,44%
EUR/USD 1,1740 -0,39%
Germany30^ 12.750,50 +0,60%
Gold spot 2.027,00 -0,40%
LDN100-24h 6.048,17 +0,33%
NY-Nasdaq Composite 10.968,36 -0,39%

Stijgers

Pharming
+8,87%
OCI
+8,64%
Neways
+7,05%
VIVORY...
+6,21%
Air Fr...
+5,88%

Dalers

NN Group
-5,88%
ADYEN NV
-4,07%
Galapagos
-4,06%
PROSUS
-3,63%
Avantium
-2,48%
 
Quotedata: Amsterdam realtime by Euronext, other realtime by Cboe Europe Ltd.   US stocks: by NYSE & Cboe BZX Exchange, 15min delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by VWD Group Crypto data by Crypto Compare